UroGen Pharma (URGN) PT Lowered to $3 at Goldman Sachs
Tweet Send to a Friend
Goldman Sachs analyst Paul Choi lowered the price target on UroGen Pharma (NASDAQ: URGN) to $3.00 (from $16.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
